This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Xeroderma pigmentosum

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Xeroderma pigmentosum is a rare, autosomal recessive condition characterised by dry photosensitive skin which is liable to freckling, keratoses and malignant transformation. The skin is sensitive to ultraviolet light because of a deficiency in at least seven enzymes required for DNA repair.

The condition begins in the first years of life when photosensitivity develops. There is early development of excessive freckling, telangiectasia, keratomas, papillomas and malignancies in sun-exposed skin, severe ophthalmic abnormalities, and in some cases, neurological disorders, particularly, progressive cerebrospinal degeneration.

  • estimated frequency is one case per 250,000 population in the United States and Europe (1)
  • within the first few years of life, BCC, SCC, sarcomas and MM start to develop if sun protection does not occur (1)

The protection of the skin from ultraviolet light is paramount.

Click here for an example image of this condition

Management (2):

  • patients will often require a multidisciplinary team-approach with dermatologists and plastic surgeons
  • genetic counselling is also needed - parents who have a child with XP have a one in four chance of having another affected child

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.